In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Aligos Therapeutics Inc (NASDAQ: ALGS) closed at $24.76 down -3.54% from its previous closing price of $25.67. In other words, the price has decreased by -$3.54 from its previous closing price. On the day, 0.59 million shares were traded. ALGS stock price reached its highest trading level at $26.84 during the session, while it also had its lowest trading level at $21.65.
Ratios:
For a deeper understanding of Aligos Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.81 and its Current Ratio is at 3.81. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on August 19, 2024, initiated with a Buy rating and assigned the stock a target price of $75.
On January 06, 2023, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $2 to $3.
Jefferies Upgraded its Hold to Buy on January 06, 2023, whereas the target price for the stock was revised from $2.50 to $3.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALGS now has a Market Capitalization of 88836160 and an Enterprise Value of 23047206. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.81 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 3.843 whereas that against EBITDA is -0.249.
Stock Price History:
The Beta on a monthly basis for ALGS is 2.47, which has changed by 0.4881159 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, ALGS has reached a high of $46.80, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is -19.92%, while the 200-Day Moving Average is calculated to be 40.66%.
Shares Statistics:
For the past three months, ALGS has traded an average of 461.46K shares per day and 231940 over the past ten days. A total of 3.20M shares are outstanding, with a floating share count of 2.64M. Insiders hold about 26.29% of the company’s shares, while institutions hold 43.88% stake in the company. Shares short for ALGS as of 1736899200 were 664384 with a Short Ratio of 1.44, compared to 1734048000 on 457104. Therefore, it implies a Short% of Shares Outstanding of 664384 and a Short% of Float of 29.56.
Earnings Estimates
The stock of Aligos Therapeutics Inc (ALGS) is currently drawing attention from 1.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$3.04, with high estimates of -$1.85 and low estimates of -$4.22.
Analysts are recommending an EPS of between -$9.21 and -$11.51 for the fiscal current year, implying an average EPS of -$10.36. EPS for the following year is -$13.01, with 2.0 analysts recommending between -$8.13 and -$17.88.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for ALGS’s current fiscal year. The highest revenue estimate was $4.6M, while the lowest revenue estimate was $3.32M, resulting in an average revenue estimate of $3.74M. In the same quarter a year ago, actual revenue was $9.34M